CA-NEXON-AMERICA
This week, MapleStory M , Nexon’s free-to-play mobile MMORPG, added the Cannoneer, an explosive and deadly new class accompanied by a playful monkey that provides attack support. A number of celebratory growth events mark the arrival of the Cannoneer, alongside a new season of the Daisy Style Festival, where mobile Maplers have the chance to earn rewards by impressing their fellow players with their fashion sense.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220318005071/en/
The Cannoneer uses its titular weapon, a deadly hand cannon forged by the Nautilus’ resident inventor, to deal massive damage with a wide attack range. This powerful pirate is accompanied by his best friend, a monkey befriended on Coco Island, who provides attack support in combat. In addition to dealing damage, the Cannoneer can use his Pirate Blessing skill to buff other characters in the same party.
This class joins MapleStory M with three celebratory events to support the growth of new Cannoneers and their adorable primate companions:
- Cannoneer On-Time Event - Login from March 16 to March 23 to receive rewards including character slot coupons, auto-battle tickets, pet packages, and more!
- Cannoneer Mega Burning Event - From March 16 to April 19, Maplers can select one character as a Mega Burning Character that will then receive 2 additional levels each time they level up.
- Cannoneer Growth Support Mission - From March 16 to April 19, Cannoneer characters can attempt various missions to receive various rewards that will support their growth. On top of growth-focused rewards, completing certain missions will also grant Cannoneer exclusive cosmetics.
This update also marks the start of Season 2 of the Daisy Style Festival , which runs until March 30. This fashion competition invites Maplers to register their characters in order to show off their sense of style and vote for the best styles from other players. Rewards including event coins, titles, and more will be awarded based on the number of votes received from fellow Maplers. Players can vote twice per day and register their style once per week, per account.
To learn more about MapleStory M, visit the App Store or Google Play Store page and follow @PlayMapleM on Twitter for the latest updates.
Assets: Artwork
Social Media: Facebook / Instagram / Twitter / Twitch / YouTube / Discord
About MapleStory M
https://maplestorym.nexon.com/
MapleStory M
, launched globally on July 24, 2018, brings the nostalgic world of side-scrolling MMORPG MapleStory
to mobile, offering the same endless amount of customization, immersive storylines and epic boss raids that fans have come to expect from the legendary franchise. MapleStory M
quickly reached 10 million downloads within 100 days after global launch and last year celebrated its 3-year anniversary with 16 million global downloads.
About Nexon America Inc.
https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory
and Mabinogi
for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220318005071/en/
Link:
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release
– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura
ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release
ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui
Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release
With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud
Vertex Announces Progress in Povetacicept Development Program and Presentation of New Data at American Society of Nephrology Kidney Week17.10.2025 15:04:00 CEST | Press release
- Food and Drug Administration grants rolling review of Biologics License Application for povetacicept in IgA nephropathy; Vertex to submit first module before end of year - - Second pivotal development program of povetacicept underway with Phase 2b/3 trial initiation in primary membranous nephropathy - - Updated data from RUBY-3 trial of povetacicept accepted for late breaking oral presentation; inaxaplin study design and APOL1-mediated kidney disease related data accepted for poster presentation - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced several important updates across its development program for povetacicept (pove), an investigational recombinant fusion protein therapeutic and dual antagonist of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines. Pove has demonstrated best-in-class potential in IgA nephropathy (IgAN) and primary membranous nephropathy (pMN) and has pipeline-in-a-product potential across a range of B c
Qualcomm Announces Quarterly Cash Dividend17.10.2025 15:00:00 CEST | Press release
Qualcomm Incorporated (NASDAQ: QCOM) today announced a quarterly cash dividend of $0.89 per common share, payable on December 18, 2025, to stockholders of record at the close of business on December 4, 2025. About Qualcomm Qualcomm relentlessly innovates to deliver intelligent computing everywhere, helping the world tackle some of its most important challenges. Building on our 40 years of technology leadership in creating era-defining breakthroughs, we deliver a broad portfolio of solutions built with our leading-edge AI, high-performance, low-power computing, and unrivaled connectivity. Our Snapdragon® platforms power extraordinary consumer experiences, and our Qualcomm Dragonwing™ products empower businesses and industries to scale to new heights. Together with our ecosystem partners, we enable next-generation digital transformation to enrich lives, improve businesses, and advance societies. At Qualcomm, we are engineering human progress. Qualcomm Incorporated includes our licensing
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom